Tasquinimod

N/A

Report date: 2023/12/26 14:45:14
NME

Base Information

Drug NameTasquinimod
Drug Alias NameTasquinimodum他喹莫德ABR-215050TASQABR-5050
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionS100 calcium binding protein A9 modulatorsHistone deacetylase 4 inhibitorsProtein allosteric inhibitors
TargetsS100 calcium binding protein A9Histone deacetylase 4
Therapy Area/IndicationsHormone-Resistant Prostate NeoplasmsPrimary MyelofibrosisThrombocythemia, Essential +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[39] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesActive Biotech Ab
China Registration ClassN/A

Develop Information

Active CompaniesErasmus University Medical CenterActive Biotech AbThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesIpsenBeaufour-Ipsen (Tianjin) Pharmaceutical Co LtdRoswell Park Cancer Institute +[8] 
Active IndicationsPrimary MyelofibrosisThrombocythemia, EssentialPolycythemia Vera +[4] 
Inactive IndicationsHormone-Resistant Prostate NeoplasmsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank